Coherus生物科學 CHRS 深 滬
已收盤 12-24 16:00:00 美东时间
1.34
+0.020
+1.52%
華盛通- 最 高1.37
- 今 開1.32
- 成交量 31.82万股
- 最 低 1.32
- 昨 收 1.32
- 總市值 1.55亿
- 52周最高 1.89
- 市盈率 靜 5.40
- 換手率 0.00%
- 52周最低 0.71
- 委 比 41.02%
- 總股本 1.16亿
- 歷史最高 38.10
- 量 比 0.42
- 振 幅 3.79%
- 歷史最低 0.6603
- 每 手 1
- 風險率 0.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Coherus Oncology's LOQTORZI Plus Chemotherapy Nearly Doubles 6-Year Survival In Recurrent/Metastatic Nasopharyngeal Carcinoma
Coherus Oncology, Inc. (NASDAQ:CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial evaluating LOQTORZI® (toripalimab-tpzi) plus chemotherapy in
12-08 21:48
SA Quant ranks Goldman's small-cap stocks with largest short interest
Goldman Sachs analysts last week identified 50 small-cap stocks with the highest short interest as a percentage of market cap, a list that was topped by Anavex Life Sciences (AVXL). The brokerage look...
11-27 04:13
Coherus Oncology Presents New Multiomic Tumor And Blood-based Biomarker Data From Phase 1b Clinical Study Evaluation CHS-114 Antibody In Patients With Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma
Coherus Oncology, Inc. (NASDAQ: CHRS), today announced new multiomic tumor and blood-based biomarker data from the dose expansion arm of its ongoing Phase 1b clinical trial evaluating CHS-114, a selective, cytolytic
11-07 22:16
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Coherus BioSciences's Earnings Outlook
Coherus BioSciences (NASDAQ:CHRS) is gearing up to announce its quarterly earni...
11-06 04:03
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025
Coherus Oncology Inc. (CHRS) announced that its third quarter 2025 financial results will be released after market close on November 6, 2025, followed by a conference call and webcast at 5:00 p.m. ET. The call will discuss financial results and provide a business update. Webcast replay and materials will be available at https://investors.coherus.com. Coherus uses this website for material non-public disclosures. The company specializes in oncolog...
10-30 12:30
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals
4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators.
10-10 16:32
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Coherus Oncology will present CHS-114, an anti-CCR8 monoclonal antibody, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 8, 2025, in Maryland. Abstract #640 highlights its selective depletion of intratumoral Tregs and immune remodeling in advanced solid tumors. Additionally, CHS-114 will be featured in a SITC webinar on October 22, 2025, discussing CCR8's role in Treg activity and immunosuppression, with i...
10-03 13:05
辉瑞中国“潮起钱塘·智启未来”第二届智慧医疗创新生态大会在杭州举办
经济观察网9月19日至20日，辉瑞中国“潮起钱塘·智启未来”第二届智慧医疗创新生态大会在杭州举办。此次大会，辉瑞现场带来V-Track院内药品科学管...
09-24 17:43
Coherus Biosciences Regains Nasdaq Compliance
An update from Coherus Biosciences ( ($CHRS) ) is now available. On June 30, 20...
09-08 22:18
